Trials show liver and weight effects
A review of 22 randomized trials of at least 40 weeks summarized that semaglutide 2.4 mg and tirzepatide (5, 10, 15 mg) met efficacy benchmarks for weight loss in adults with and without diabetes. (ajmc.com). Reuters and university reports also describe emerging evidence that GLP‑1 drugs can improve markers of liver and heart health independent of major weight loss. (reuters.com).
Drugs first sold for diabetes and then for weight loss are now showing signs of helping the liver and the heart, even when patients do not lose much weight. (ajmc.com) (aol.com) (massgeneralbrigham.org) A 2025 review summarized 22 randomized trials lasting at least 40 weeks and found that semaglutide 2.4 milligrams and tirzepatide at 5, 10, and 15 milligrams met weight-loss efficacy benchmarks in adults with and without type 2 diabetes. Gastrointestinal side effects were common, but pancreatitis and serious adverse events were similar to placebo in the review. (ajmc.com) The same review, covering more than 40,000 adults, reported that tirzepatide and semaglutide produced the largest weight reductions among the drugs studied. In examples cited by the review, tirzepatide 15 milligrams cut body weight by 9.5 kilograms at 40 weeks in SURPASS-1, while semaglutide 2.4 milligrams reduced body weight by 9.6% at 68 weeks. (ajmc.com) These medicines mimic gut hormones that help regulate appetite and blood sugar. Researchers have been trying to sort out how much of their benefit comes from weight loss itself and how much comes from direct effects inside organs such as the liver and blood vessels. (cell.com) (nature.com) On April 15, 2026, Reuters reported results from a mouse study showing semaglutide acted directly on liver sinusoidal endothelial cells, a small group that makes up about 3% of liver cells and lines tiny liver blood vessels. The researchers said the drug changed gene activity in those cells and reduced liver inflammation independent of its effects on obesity. (aol.com) (cell.com) Sinai Health said the work was published in Cell Metabolism on April 14, 2026, and identified liver sinusoidal endothelial cells and immune T cells as carrying receptors for semaglutide. The study focused on mice with metabolic dysfunction-associated steatohepatitis, a severe form of fatty liver disease marked by inflammation and scarring. (sinaihealth.ca) (cell.com) Heart findings are further along than the liver mechanism work. A Nature Medicine study published on November 9, 2025 found semaglutide and tirzepatide delivered comparable cardiovascular benefit in U.S. clinical practice, with a head-to-head hazard ratio of 1.06 for heart attack, stroke, or death, a result the authors said supported similar protection. (nature.com) Mass General Brigham, which released the study with the American Heart Association meeting in November 2025, said semaglutide lowered stroke and heart attack risk by 18% versus sitagliptin, while tirzepatide lowered stroke, heart attack, and death by 13% versus dulaglutide. The researchers said the early timing of those benefits suggested mechanisms beyond weight loss alone. (massgeneralbrigham.org) The liver evidence is not all at the same stage. The April 2026 liver mechanism study was done in mice, while the weight-loss evidence comes from randomized trials in people and the cardiovascular comparisons include large real-world human data. (aol.com) (ajmc.com) (nature.com) For doctors and patients, that means the scale is still only one measure. The newer data suggest semaglutide and tirzepatide can reduce weight reliably, while separate lines of research are building a case that they may also protect the liver and heart through additional pathways. (ajmc.com) (sinaihealth.ca) (nature.com)
